Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Cash & Equivalents for 3 consecutive years, with $141.9 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 71.72% year-over-year to $141.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $141.9 million (down 71.72% YoY) and the FY2025 annual result came in at $141.9 million, down 67.76% from the prior year.
• Cash & Equivalents eased to $141.9 million in Q4 2025 per TLX's latest filing, from $501.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TLX reached as high as $501.7 million in Q4 2024 and fell as low as $87.0 million in Q4 2023.
• A 3-year average of $243.5 million and a median of $141.9 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 476.41% — and 2025, when it plunged 71.72%.
• Year by year, Cash & Equivalents stood at $87.0 million in 2023, then soared by 476.41% to $501.7 million in 2024, then slumped by 71.72% to $141.9 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $141.9 million, $501.7 million, and $87.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.